Parallel Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Parallel Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$532	Sell	87 -82	-49%	-$536	﹤0.01%	3781
2026 Q1	$1.17K	Buy	169 +82	+94%	+$632	﹤0.01%	3508
2025 Q4	$767	Hold	87	–	–	﹤0.01%	3344
2025 Q3	$434	Hold	87	–	–	﹤0.01%	3348
2025 Q2	$411	Hold	87	–	–	﹤0.01%	3330
2025 Q1	$399	Hold	87	–	–	﹤0.01%	3270
2024 Q4	$417	Hold	87	–	–	﹤0.01%	3256
2024 Q3	$408	Hold	87	–	–	﹤0.01%	3212
2024 Q2	$492	Hold	87	–	–	﹤0.01%	3099
2024 Q1	$358	Buy	+87	New	+$348	﹤0.01%	3095
2023 Q3	–	Sell	-2,207	Closed	-$14.5K	–	3491
2023 Q2	$14.5K	Buy	2,207 +1,442	+188%	+$9.24K	﹤0.01%	2006
2023 Q1	$5.19K	Buy	765 +285	+59%	+$2K	﹤0.01%	2396
2022 Q4	$3.55K	Buy	480 +354	+281%	+$3.45K	﹤0.01%	2469
2022 Q3	$1K	Buy	+126	New	+$1.33K	﹤0.01%	3037
2022 Q1	–	Sell	-46	Closed	-$1K	–	3291
2021 Q4	$1K	Hold	46	–	–	﹤0.01%	2975
2021 Q3	$1K	Buy	+46	New	+$806	﹤0.01%	2974
2017 Q3	–	Sell	-13	Closed	–	–	2223
2017 Q2	$0	Buy	+13	New	+$187	﹤0.01%	2217

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parallel Advisors's VNDA Position: Q2 2026 in Review

Parallel Advisors reduced its Vanda Pharmaceuticals (VNDA) stake by 49% in Q2 2026, selling an estimated $536 and leaving 87 shares worth $532. The position accounts for ﹤0.01% of the portfolio, ranked #3781.

Parallel Advisors first reported a position in VNDA in Q2 2017 and has held it in 17 quarters since. The position peaked at $14.5K in Q2 2023. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Parallel Advisors held 87 shares of Vanda Pharmaceuticals worth $532 as of Q2 2026.
Parallel Advisors sold 82 Vanda Pharmaceuticals shares in Q2 2026, an estimated $536.
Vanda Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3781 holding.
Parallel Advisors first reported a position in Vanda Pharmaceuticals in Q2 2017 and has held it in 17 quarters since.
Parallel Advisors's Vanda Pharmaceuticals position peaked at $14.5K in Q2 2023.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.